{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T12:41:09Z","timestamp":1782132069915,"version":"3.54.5"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009392","name":"Prince Sattam bin Abdulaziz University","doi-asserted-by":"publisher","award":["PSAU\/2024\/01\/31616"],"award-info":[{"award-number":["PSAU\/2024\/01\/31616"]}],"id":[{"id":"10.13039\/100009392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Microvascular Research"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.mvr.2026.104925","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T16:50:15Z","timestamp":1771865415000},"page":"104925","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The possible role of PCSK9 inhibitors in cardiac syndrome X: Bridging microvascular dysfunction, endothelial pathobiology, and molecular pharmacotherapy"],"prefix":"10.1016","volume":"165","author":[{"given":"Sherouk Hussein","family":"Sweilam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayder M.","family":"Al-kuraishy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya M.","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaimaa M.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Alsharari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaber El-Saber","family":"Batiha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.mvr.2026.104925_bb0005","doi-asserted-by":"crossref","DOI":"10.3390\/ph17121581","article-title":"PCSK9 inhibitors: focus on Evolocumab and its impact on atherosclerosis progression","volume":"17","author":"Abduljabbar","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"issue":"6","key":"10.1016\/j.mvr.2026.104925_bb0010","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1007\/s10787-024-01529-5","article-title":"Atheroprotective role of vinpocetine: an old drug with new indication","volume":"32","author":"Abu-Alghayth","year":"2024","journal-title":"Inflammopharmacology"},{"issue":"23","key":"10.1016\/j.mvr.2026.104925_bb0015","doi-asserted-by":"crossref","first-page":"15513","DOI":"10.1021\/acs.jmedchem.2c01290","article-title":"Recent update on the development of PCSK9 inhibitors for hypercholesterolemia treatment","volume":"65","author":"Ahamad","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.mvr.2026.104925_bb0020","doi-asserted-by":"crossref","DOI":"10.15420\/ecr.2021.15","article-title":"Microvascular angina: diagnosis and management","volume":"16","author":"Aldiwani","year":"2021","journal-title":"Eur. Cardiol."},{"issue":"1","key":"10.1016\/j.mvr.2026.104925_bb0025","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4103\/IJCIIS.IJCIIS_49_20","article-title":"Statin therapy improves serum Annexin A1 levels in patients with acute coronary syndrome: a case-controlled study","volume":"11","author":"Al-Kuraishy","year":"2021","journal-title":"Int. J. Crit. Illn. Inj. Sci."},{"issue":"8","key":"10.1016\/j.mvr.2026.104925_bb0030","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1007\/s11010-023-04816-x","article-title":"Possible role of LCZ696 in atherosclerosis: new inroads and perspective","volume":"479","author":"Al-Kuraishy","year":"2024","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.mvr.2026.104925_bb0035","article-title":"The role of autophagy in graves disease: knowns and unknowns","volume":"12","author":"Al-Kuraishy","year":"2024","journal-title":"Front. Cell Dev. Biol."},{"issue":"Pt 1","key":"10.1016\/j.mvr.2026.104925_bb0040","article-title":"The mechanistic role of tirzepatide in atherosclerosis: a review","volume":"329","author":"Al-Kuraishy","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"issue":"1","key":"10.1016\/j.mvr.2026.104925_bb0045","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13044-024-00199-3","article-title":"Increased thyroid stimulating hormone (TSH) as a possible risk factor for atherosclerosis in subclinical hypothyroidism","volume":"17","author":"Alomair","year":"2024","journal-title":"Thyroid. Res."},{"issue":"13","key":"10.1016\/j.mvr.2026.104925_bb0050","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1111\/jcmm.17784","article-title":"NF-\u03baB\/NLRP3 inflammasome axis and risk of Parkinson\u2019s disease in type 2 diabetes mellitus: a narrative review and new perspective","volume":"27","author":"Alrouji","year":"2023","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.mvr.2026.104925_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2020.602497","article-title":"PCSK9 in myocardial infarction and cardioprotection: importance of lipid metabolism and inflammation","volume":"11","author":"Andreadou","year":"2020","journal-title":"Front. Physiol."},{"issue":"3","key":"10.1016\/j.mvr.2026.104925_bb0060","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/cvr\/cvab061","article-title":"Prevalence of microvascular angina among patients with stable symptoms in the absence of obstructive coronary artery disease: a systematic review","volume":"118","author":"Aribas","year":"2022","journal-title":"Cardiovasc. Res."},{"issue":"11","key":"10.1016\/j.mvr.2026.104925_bb0065","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1161\/CIRCULATIONAHA.116.024534","article-title":"Ischemia and no obstructive coronary artery disease (INOCA): developing evidence-based therapies and research agenda for the next decade","volume":"135","author":"Bairey Merz","year":"2017","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.mvr.2026.104925_bb0070","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1161\/CIRCULATIONAHA.116.024534","article-title":"Ischemia and no obstructive coronary artery disease (INOCA) developing evidence-based therapies and research agenda for the next decade","volume":"135","author":"Bairey Merz","year":"2017","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.mvr.2026.104925_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26031003","article-title":"PCSK9 expression in vascular smooth muscle cells: role of insulin resistance and high glucose","volume":"26","author":"Barale","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.mvr.2026.104925_bb0080","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of Alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.mvr.2026.104925_bb0085","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s12350-022-02974-x","article-title":"Definition and epidemiology of coronary microvascular disease","volume":"29","author":"Bradley","year":"2022","journal-title":"J. Nucl. Cardiol."},{"issue":"8","key":"10.1016\/j.mvr.2026.104925_bb0090","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jacc.2017.11.069","article-title":"PCSK9 as a positive modulator of platelet activation","volume":"71","author":"Camera","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"8","key":"10.1016\/j.mvr.2026.104925_bb0095","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMra061889","article-title":"Coronary microvascular dysfunction","volume":"356","author":"Camici","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.mvr.2026.104925_bb0100","doi-asserted-by":"crossref","first-page":"983","DOI":"10.21037\/atm-22-3976","article-title":"Exploring the mechanism of Shexiang Tongxin dropping pill in the treatment of microvascular angina through network pharmacology and molecular docking","volume":"10","author":"Chang","year":"2022","journal-title":"Ann. Transl. Med."},{"issue":"1","key":"10.1016\/j.mvr.2026.104925_bb0105","doi-asserted-by":"crossref","first-page":"6129","DOI":"10.1038\/s41598-019-42700-1","article-title":"Association between insulin resistance, hyperglycemia, and coronary artery disease according to the presence of diabetes","volume":"9","author":"Cho","year":"2019","journal-title":"Sci. Rep."},{"issue":"19","key":"10.1016\/j.mvr.2026.104925_bb0110","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1161\/01.CIR.102.19.2359","article-title":"Endothelial activation in patients with cardiac syndrome X","volume":"102","author":"Desideri","year":"2000","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.mvr.2026.104925_bb0115","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/cvr\/cvy128","article-title":"PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy","volume":"114","author":"Ding","year":"2018","journal-title":"Cardiovasc. Res."},{"issue":"2","key":"10.1016\/j.mvr.2026.104925_bb0120","doi-asserted-by":"crossref","first-page":"531","DOI":"10.7150\/thno.80289","article-title":"SIRT3 mediates the effects of PCSK9 inhibitors on inflammation, autophagy, and oxidative stress in endothelial cells","volume":"13","author":"D'Onofrio","year":"2023","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.mvr.2026.104925_bb0125","doi-asserted-by":"crossref","first-page":"531","DOI":"10.7150\/thno.80289","article-title":"SIRT3 mediates the effects of PCSK9 inhibitors on inflammation, autophagy, and oxidative stress in endothelial cells","volume":"13","author":"D'Onofrio","year":"2023","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.mvr.2026.104925_bb0130","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/HYPERTENSIONAHA.119.12919","article-title":"Endothelin receptor antagonism improves lipid profiles and lowers PCSK9 (Proprotein convertase Subtilisin\/Kexin type 9) in patients with chronic kidney disease","volume":"74","author":"Farrah","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.mvr.2026.104925_bb0135","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.894685","article-title":"Real-world safety of PCSK9 inhibitors: a pharmacovigilance study based on spontaneous reports in FAERS","volume":"13","author":"Feng","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.mvr.2026.104925_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101662","article-title":"Molecular interactions of PCSK9 with an inhibitory nanobody, CAP1 and HLA-C: functional regulation of LDLR levels","volume":"67","author":"Fruchart Gaillard","year":"2023","journal-title":"Mol. Metab."},{"issue":"1","key":"10.1016\/j.mvr.2026.104925_bb0145","doi-asserted-by":"crossref","DOI":"10.1186\/s12944-021-01478-w","article-title":"Pcsk9 is associated with severity of coronary artery lesions in male patients with premature myocardial infarction","volume":"20","author":"Gao","year":"2021","journal-title":"Lipids Health Dis."},{"issue":"12","key":"10.1016\/j.mvr.2026.104925_bb0150","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1007\/s11427-023-2688-8","article-title":"Increase of PCSK9 expression in diabetes promotes VEGFR2 ubiquitination to inhibit endothelial function and skin wound healing","volume":"67","author":"Gao","year":"2024","journal-title":"Sci. China Life Sci."},{"issue":"3","key":"10.1016\/j.mvr.2026.104925_bb0155","doi-asserted-by":"crossref","DOI":"10.1177\/00368504251370679","article-title":"Pcsk9 in peripheral arterial disease: mechanisms and therapeutic perspectives","volume":"108","author":"Gao","year":"2025","journal-title":"Sci. Prog."},{"key":"10.1016\/j.mvr.2026.104925_bb0160","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.atherosclerosis.2016.06.011","article-title":"A single injection of gain-of-function mutant PCSK9 adeno-associated virus vector induces cardiovascular calcification in mice with no genetic modification","volume":"251","author":"Goettsch","year":"2016","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.mvr.2026.104925_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031070","article-title":"Emerging insights on the diverse roles of Proprotein convertase Subtilisin\/Kexin type 9 (PCSK9) in chronic liver diseases: cholesterol metabolism and beyond","volume":"23","author":"Grewal","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"21","key":"10.1016\/j.mvr.2026.104925_bb0170","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1161\/CIRCULATIONAHA.124.072336","article-title":"PCSK9 promotes LDLR degradation by preventing SNX17-mediated LDLR recycling","volume":"151","author":"Guan","year":"2025","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.mvr.2026.104925_bb0175","doi-asserted-by":"crossref","DOI":"10.31083\/RCM25757","article-title":"Coronary microvascular dysfunction: insights on prognosis and future perspectives","volume":"26","author":"Gurgoglione","year":"2025","journal-title":"Rev. Cardiovasc. Med."},{"key":"10.1016\/j.mvr.2026.104925_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.mvr.2022.104371","article-title":"PCSK9 inhibition protects against myocardial ischemia-reperfusion injury via suppressing autophagy","volume":"142","author":"Huang","year":"2022","journal-title":"Microvasc. Res."},{"issue":"1","key":"10.1016\/j.mvr.2026.104925_bb0185","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s10753-022-01715-z","article-title":"PCSK9 promotes endothelial dysfunction during Sepsis via the TLR4\/MyD88\/NF-\u03baB and NLRP3 pathways","volume":"46","author":"Huang","year":"2023","journal-title":"Inflammation"},{"issue":"8","key":"10.1016\/j.mvr.2026.104925_bb0190","doi-asserted-by":"crossref","first-page":"e647","DOI":"10.4244\/EIJ-D-22-00269","article-title":"Evolocumab for prevention of microvascular dysfunction in patients undergoing percutaneous coronary intervention: the randomised, open-label EVOCATION trial","volume":"18","author":"Ishihara","year":"2022","journal-title":"EuroIntervention"},{"issue":"5","key":"10.1016\/j.mvr.2026.104925_bb0195","first-page":"3586","article-title":"Effects of early PCSK9 inhibitor application on inflammation levels and microcirculatory function after PCI in patients with NSTE-ACS","volume":"15","author":"Ji","year":"2023","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.mvr.2026.104925_bb0200","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.925923","article-title":"Mechanisms of oxidized LDL-mediated endothelial dysfunction and its consequences for the development of atherosclerosis","volume":"9","author":"Jiang","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"issue":"9","key":"10.1016\/j.mvr.2026.104925_bb0205","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jacc.2019.03.013","article-title":"Alirocumab in patients with Polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES trial","volume":"74","author":"Jukema","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.mvr.2026.104925_bb0210","doi-asserted-by":"crossref","first-page":"76","DOI":"10.51789\/cmsj.2021.1.e4","article-title":"Differences in clinical characteristics between men and post-menopausal women with chest pain who have normal coronary arteries","volume":"1","author":"Kim","year":"2021","journal-title":"CardioMetab. Syndr. J."},{"key":"10.1016\/j.mvr.2026.104925_bb0215","series-title":"Cholesterol, Lipoproteins, and Cardiovascular Health: Separating the Good (HDL), the Bad (LDL), and the Remnant","author":"Kontush","year":"2024"},{"issue":"13","key":"10.1016\/j.mvr.2026.104925_bb0220","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.4244\/EIJY20M07_01","volume":"16","author":"Kunadian","year":"2021","journal-title":"EuroIntervention"},{"issue":"9","key":"10.1016\/j.mvr.2026.104925_bb0225","first-page":"27","article-title":"PCSK9 inhibitor causes a decrease in the level of oxidatively modified low-density lipoproteins in patients with coronary artery diseases","volume":"90","author":"Lankin","year":"2018","journal-title":"Ter. Arkh."},{"issue":"21","key":"10.1016\/j.mvr.2026.104925_bb0230","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1161\/CIRCULATIONAHA.109.900191","article-title":"Primary coronary microvascular dysfunction: clinical presentation, pathophysiology, and management","volume":"121","author":"Lanza","year":"2010","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.mvr.2026.104925_bb0235","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-28240-9","article-title":"Caffeine blocks SREBP2-induced hepatic PCSK9 expression to enhance LDLR-mediated cholesterol clearance","volume":"13","author":"Lebeau","year":"2022","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.mvr.2026.104925_bb0240","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1161\/CIRCULATIONAHA.120.046320","article-title":"Effect of evolocumab on atherogenic lipoproteins during the peri- and early postinfarction period: a placebo-controlled, randomized trial","volume":"142","author":"Leucker","year":"2020","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.mvr.2026.104925_bb0245","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016263","article-title":"Evolocumab, a PCSK9-monoclonal antibody, rapidly reverses coronary artery endothelial dysfunction in people living with HIV and people with dyslipidemia","volume":"9","author":"Leucker","year":"2020","journal-title":"J. Am. Heart Assoc."},{"issue":"12","key":"10.1016\/j.mvr.2026.104925_bb0250","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12122729","article-title":"Pleiotropic effects of PCSK9 inhibitors on cardio-cerebrovascular diseases","volume":"12","author":"Li","year":"2024","journal-title":"Biomedicines"},{"issue":"9","key":"10.1016\/j.mvr.2026.104925_bb0255","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.7150\/thno.83914","article-title":"PCSK9 attenuates efferocytosis in endothelial cells and promotes vascular aging","volume":"13","author":"Liu","year":"2023","journal-title":"Theranostics"},{"issue":"7","key":"10.1016\/j.mvr.2026.104925_bb0260","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s11655-023-3545-z","article-title":"Research on hepatocyte regulation of PCSK9-LDLR and its related drug targets","volume":"30","author":"Liu","year":"2024","journal-title":"Chin. J. Integr. Med."},{"issue":"5","key":"10.1016\/j.mvr.2026.104925_bb0265","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202101660RR","article-title":"Differential cholesterol uptake in liver cells: a role for PCSK9","volume":"36","author":"Luquero","year":"2022","journal-title":"FASEB J."},{"issue":"16","key":"10.1016\/j.mvr.2026.104925_bb0270","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12165284","article-title":"Dual antiplatelet therapy or antiplatelet plus anticoagulant therapy in patients with peripheral and chronic coronary artery disease: an updated review","volume":"12","author":"Magnani","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.mvr.2026.104925_bb0275","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.atherosclerosis.2018.01.032","article-title":"Noncanonical NF-\u03baB signaling in microvessels of atherosclerotic lesions is associated with inflammation, atheromatous plaque morphology and myocardial infarction","volume":"270","author":"Maracle","year":"2018","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.mvr.2026.104925_bb0280","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s11658-023-00482-5","article-title":"MiR-15b-5p and PCSK9 inhibition reduces lipopolysaccharide-induced endothelial dysfunction by targeting SIRT4","volume":"28","author":"Martino","year":"2023","journal-title":"Cell. Mol. Biol. Lett."},{"issue":"1","key":"10.1016\/j.mvr.2026.104925_bb0285","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/1871529X23666230503123612","article-title":"Autophagy behavior in post-myocardial infarction injury","volume":"23","author":"Marzoog","year":"2023","journal-title":"Cardiovasc. Hematol. Disord. Drug Targets"},{"issue":"21","key":"10.1016\/j.mvr.2026.104925_bb0290","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1161\/CIRCULATIONAHA.124.069901","article-title":"Zibotentan in microvascular angina: a randomized, placebo-controlled, crossover trial","volume":"150","author":"Morrow","year":"2024","journal-title":"Circulation"},{"issue":"45","key":"10.1016\/j.mvr.2026.104925_bb0295","doi-asserted-by":"crossref","first-page":"11737","DOI":"10.1021\/acs.jpcb.5c05530","article-title":"Mixed-solvent molecular dynamics simulation reveals a Druggable allosteric pocket in the PCSK9 C-terminal domain","volume":"129","author":"Mukhopadhyay","year":"2025","journal-title":"J. Phys. Chem. B"},{"issue":"3","key":"10.1016\/j.mvr.2026.104925_bb0300","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1160\/TH14-11-0947","article-title":"Platelets, inflammation and anti-inflammatory effects of antiplatelet drugs in ACS and CAD","volume":"114","author":"M\u00fcller","year":"2015","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.mvr.2026.104925_bb0305","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1146\/annurev-med-080819-044918","article-title":"Treating coronary artery disease: beyond statins, ezetimibe, and PCSK9 inhibition","volume":"72","author":"Musunuru","year":"2021","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.mvr.2026.104925_bb0310","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ijcard.2016.10.084","article-title":"Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: the PCSK9-REACT study","volume":"227","author":"Navarese","year":"2017","journal-title":"Int. J. Cardiol."},{"issue":"22","key":"10.1016\/j.mvr.2026.104925_bb0315","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of Evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"Jama"},{"issue":"5","key":"10.1016\/j.mvr.2026.104925_bb0320","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/14740338.2020.1747431","article-title":"An overview of statin-induced myopathy and perspectives for the future","volume":"19","author":"Nikolic","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"issue":"12","key":"10.1016\/j.mvr.2026.104925_bb0325","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O\u2019Donoghue","year":"2019","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.mvr.2026.104925_bb0330","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14165897","article-title":"The relationship between cardiac syndrome X and obstructive sleep apnea and the effects of sleep apnea treatment on myocardial ischemia","volume":"14","author":"Ozturk","year":"2025","journal-title":"J. Clin. Med."},{"issue":"03","key":"10.1016\/j.mvr.2026.104925_bb0335","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1055\/s-0038-1676863","article-title":"PCSK9 in haemostasis and thrombosis: possible pleiotropic effects of PCSK9 inhibitors in cardiovascular prevention","volume":"119","author":"Paciullo","year":"2019","journal-title":"Thromb. Haemost."},{"issue":"11","key":"10.1016\/j.mvr.2026.104925_bb0340","doi-asserted-by":"crossref","first-page":"7310","DOI":"10.1111\/jcmm.14586","article-title":"PCSK9 inhibitor improves cardiac function and reduces infarct size in rats with ischaemia\/reperfusion injury: benefits beyond lipid-lowering effects","volume":"23","author":"Palee","year":"2019","journal-title":"J. Cell. Mol. Med."},{"issue":"1","key":"10.1016\/j.mvr.2026.104925_bb0345","doi-asserted-by":"crossref","DOI":"10.1186\/s12944-022-01751-6","article-title":"PCSK9 inhibition and cholesterol homeostasis in insulin producing \u03b2-cells","volume":"21","author":"P\u00e4th","year":"2022","journal-title":"Lipids Health Dis."},{"issue":"3","key":"10.1016\/j.mvr.2026.104925_bb0350","article-title":"Endothelial dysfunction: redox imbalance, NLRP3 Inflammasome, and inflammatory responses in cardiovascular diseases","volume":"14","author":"Penna","year":"2025","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.mvr.2026.104925_bb0355","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/726539","article-title":"Nitric oxide synthetic pathway in patients with microvascular angina and its relations with oxidative stress","volume":"2014","author":"Porro","year":"2014","journal-title":"Oxidative Med. Cell. Longev."},{"issue":"3","key":"10.1016\/j.mvr.2026.104925_bb0360","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023328","article-title":"Effects of PCSK9 targeting: alleviating oxidation, inflammation, and atherosclerosis","volume":"11","author":"Punch","year":"2022","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"10.1016\/j.mvr.2026.104925_bb0365","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1161\/CIRCULATIONAHA.120.046290","article-title":"PCSK9 (Proprotein convertase Subtilisin\/Kexin 9) enhances platelet activation, thrombosis, and myocardial infarct expansion by binding to platelet CD36","volume":"143","author":"Qi","year":"2021","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.mvr.2026.104925_bb0370","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/j.numecd.2021.03.026","article-title":"The effect of PCSK9 inhibitors on brain stroke prevention: a systematic review and meta-analysis","volume":"31","author":"Qin","year":"2021","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"issue":"16","key":"10.1016\/j.mvr.2026.104925_bb0375","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.mvr.2026.104925_bb0380","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.mvr.2026.104925_bb0385","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.2337\/dc18-2356","article-title":"Effects of metformin therapy on coronary endothelial dysfunction in patients with prediabetes with stable angina and nonobstructive coronary artery stenosis: the CODYCE multicenter prospective study","volume":"42","author":"Sardu","year":"2019","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.mvr.2026.104925_bb0390","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021510","article-title":"Endothelial dysfunction drives CRTd outcome at 1-year follow-up: a novel role as biomarker for miR-130a-5p","volume":"24","author":"Sardu","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mvr.2026.104925_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2025.101349","article-title":"Endothelial dysfunction and cardiovascular outcomes in pre-menopausal women with high vs low breast fat accumulation: the role of TSP-1","volume":"24","author":"Sardu","year":"2025","journal-title":"Am. J. Prev. Cardiol."},{"issue":"8","key":"10.1016\/j.mvr.2026.104925_bb0400","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1074\/jbc.RA119.010221","article-title":"A transient amphipathic helix in the prodomain of PCSK9 facilitates binding to low-density lipoprotein particles","volume":"295","author":"Sarkar","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mvr.2026.104925_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.mvr.2023.104513","article-title":"Chronic PCSK9 inhibitor therapy leads to sustained improvements in endothelial function, arterial stiffness, and microvascular function","volume":"148","author":"Schremmer","year":"2023","journal-title":"Microvasc. Res."},{"issue":"3","key":"10.1016\/j.mvr.2026.104925_bb0410","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1210\/endrev\/bnab035","article-title":"The multifaceted biology of PCSK9","volume":"43","author":"Seidah","year":"2022","journal-title":"Endocr. Rev."},{"issue":"1","key":"10.1016\/j.mvr.2026.104925_bb0415","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1124\/pr.116.012989","article-title":"The Proprotein convertases in hypercholesterolemia and cardiovascular diseases: emphasis on Proprotein convertase Subtilisin\/Kexin 9","volume":"69","author":"Seidah","year":"2017","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.mvr.2026.104925_bb0420","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.5114\/amsad.2019.86752","article-title":"Can metformin stabilize PCSK9 level in stable coronary artery disease patients treated with statins?","volume":"4","author":"Shek","year":"2019","journal-title":"Arch. Med. Sci. Atheroscler. Dis."},{"issue":"3","key":"10.1016\/j.mvr.2026.104925_bb0425","article-title":"Treatment with PCSK9 inhibitor Evolocumab improves vascular oxidative stress and arterial stiffness in Hypercholesterolemic patients with high cardiovascular risk","volume":"12","author":"Silla","year":"2023","journal-title":"Antioxidants (Basel)"},{"issue":"1","key":"10.1016\/j.mvr.2026.104925_bb0430","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12933-022-01584-8","article-title":"Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial","volume":"21","author":"Sposito","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"issue":"5","key":"10.1016\/j.mvr.2026.104925_bb0435","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/00033197211034267","article-title":"Biomarkers of coronary microvascular dysfunction in patients with microvascular angina: a narrative review","volume":"73","author":"Sucato","year":"2022","journal-title":"Angiology"},{"issue":"6","key":"10.1016\/j.mvr.2026.104925_bb0440","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00210-022-02200-y","article-title":"Antitumor activity and molecular mechanism of proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibition","volume":"395","author":"Sun","year":"2022","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.mvr.2026.104925_bb0445","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.atherosclerosis.2017.04.023","article-title":"New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4\/NF-\u03baB pathway","volume":"262","author":"Tang","year":"2017","journal-title":"Atherosclerosis"},{"issue":"9","key":"10.1016\/j.mvr.2026.104925_bb0450","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1080\/1061186X.2022.2092622","article-title":"Molecular and cellular biology of PCSK9: impact on glucose homeostasis","volume":"30","author":"Tch\u00e9oubi","year":"2022","journal-title":"J. Drug Target."},{"issue":"3","key":"10.1016\/j.mvr.2026.104925_bb0455","doi-asserted-by":"crossref","DOI":"10.31083\/j.jin2303062","article-title":"The impact of PCSK9 gene polymorphisms on ischemic stroke: a systematic review and meta-analysis","volume":"23","author":"Wang","year":"2024","journal-title":"J. Integr. Neurosci."},{"issue":"4","key":"10.1016\/j.mvr.2026.104925_bb0460","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1177\/0300060516648030","article-title":"Proprotein convertase subtilisin\/kexin type 9 levels and aortic valve calcification: a prospective, cross sectional study","volume":"44","author":"Wang","year":"2016","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.mvr.2026.104925_bb0465","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12933-016-0353-1","article-title":"Insulin resistance, endothelial function, angiogenic factors and clinical outcome in non-diabetic patients with chest pain without myocardial perfusion defects","volume":"15","author":"Westergren","year":"2016","journal-title":"Cardiovasc. Diabetol."},{"issue":"6","key":"10.1016\/j.mvr.2026.104925_bb0470","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/jnnp-2023-332392","article-title":"PCSK9 inhibitors reduced early recurrent stroke in patients with symptomatic intracranial atherosclerotic stenosis","volume":"95","author":"Wu","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.mvr.2026.104925_bb0475","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.764038","article-title":"Regulation of PCSK9 expression and function: mechanisms and therapeutic implications","volume":"8","author":"Xia","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"issue":"1","key":"10.1016\/j.mvr.2026.104925_bb0480","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1186\/s40001-025-02937-1","article-title":"Targeting proprotein convertase subtilisin\/kexin type 9 (PCSK9) to tackle central nervous system diseases: role as a promising approach","volume":"30","author":"Zheng","year":"2025","journal-title":"Eur. J. Med. Res."},{"issue":"7","key":"10.1016\/j.mvr.2026.104925_bb0485","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/ehjcvp\/pvad051","article-title":"Platelet activation and endothelial dysfunction biomarkers in acute coronary syndrome: the impact of PCSK9 inhibition","volume":"9","author":"Ziogos","year":"2023","journal-title":"Eur. Heart J. Cardiovasc. Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.mvr.2026.104925_bb0490","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065098","article-title":"PCSK9 inhibitors reduce PCSK9 and early Atherogenic biomarkers in stimulated human coronary artery endothelial cells","volume":"24","author":"Zulkapli","year":"2023","journal-title":"Int. J. Mol. Sci."}],"container-title":["Microvascular Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026286226000257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026286226000257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T06:53:27Z","timestamp":1777445607000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026286226000257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":98,"alternative-id":["S0026286226000257"],"URL":"https:\/\/doi.org\/10.1016\/j.mvr.2026.104925","relation":{},"ISSN":["0026-2862"],"issn-type":[{"value":"0026-2862","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The possible role of PCSK9 inhibitors in cardiac syndrome X: Bridging microvascular dysfunction, endothelial pathobiology, and molecular pharmacotherapy","name":"articletitle","label":"Article Title"},{"value":"Microvascular Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mvr.2026.104925","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104925"}}